Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA

Connect Tissue Res. 1989;19(2-4):243-53. doi: 10.3109/03008208909043899.

Abstract

We have developed a new ELISA to quantify hyaluronate. This ELISA takes advantage of an anti-keratan sulfate antibody to differentiate between the coated aggregating rat chondrosarcoma proteoglycan which captures the hyaluronate and the keratan sulfate-bearing aggregating proteoglycan added subsequently. Absorbance in this assay was shown to be linear to the logarithmic concentration of hyaluronate in the range of 15 to 1000 ng/ml. Pre-treatment of hyaluronate with papain or protease did not interfere with its quantification; in contrast, pre-treatment with 0.1N NaOH significantly interferes with the subsequent measurement of the hyaluronate molecules. The size of the hyaluronate molecule was found to be an important factor in quantification: only large size hyaluronate molecules could be quantified accurately. The ELISA was used to show that human lung carcinomas contain 2 to 500 times as much hyaluronate as normal lung tissue from the same patient.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal
  • Carcinoma / analysis*
  • Chondroitin Sulfate Proteoglycans / immunology
  • Chromatography, Gel
  • Enzyme-Linked Immunosorbent Assay / instrumentation*
  • Humans
  • Hyaluronic Acid / analysis*
  • Hydrogen-Ion Concentration
  • Keratan Sulfate / immunology
  • Lumican
  • Lung / analysis
  • Lung Neoplasms / analysis*
  • Molecular Weight

Substances

  • Antibodies, Monoclonal
  • Chondroitin Sulfate Proteoglycans
  • LUM protein, human
  • Lum protein, rat
  • Lumican
  • Hyaluronic Acid
  • Keratan Sulfate